{"schema_version":"secwatch.filing_event.v1","accession":"0001787306-24-000151","form_type":"8-K","ticker":"ARQT","cik":"0001787306","company_name":"Arcutis Biotherapeutics, Inc.","filed_at":"2024-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.630442+00:00","generated_at":"2026-05-30T04:43:08.588169+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Arcutis Q3 revenue $44.8M (+452% YoY); net loss narrows to $41.5M","bullets":["ZORYVE franchise revenue $44.8M ($22.0M cream 0.3%, $20.3M foam 0.3%, $2.5M cream 0.15%), up 45% QoQ.","Net loss $41.5M ($0.33/sh) vs $44.8M ($0.73/sh) in Q3 '23; operating cash burn improved 23% QoQ to $34.7M.","Blended gross-to-net improved to low 50% range from high 50% last quarter; approaching steady state for foam.","Amended $200M SLR loan: lower rate, maturity extended to Aug '29; prepaid $100M on Oct 8, 2024.","sNDA for ZORYVE foam in scalp/body psoriasis accepted; PDUFA May 22, 2025. Health Canada approval for foam in SD received."],"urls":{"canonical":"https://secwatch.observer/filing/0001787306-24-000151","json":"https://secwatch.observer/filing/0001787306-24-000151.json","markdown":"https://secwatch.observer/filing/0001787306-24-000151.md","text":"https://secwatch.observer/filing/0001787306-24-000151.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787306/000178730624000151/0001787306-24-000151-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787306/000178730624000151/arqt-20241106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:43:08.588169+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}